When does the Eliquis (apixaban) patent expire?
Eliquis is the brand name for apixaban, an oral anticoagulant. Patent “expiry” depends on which specific patent is being referenced (drug substance, formulation, specific dosing/regimen, or manufacturing). Different patents can expire in different years, and marketing exclusivity rules can extend market protection beyond the first patent term.
For a targeted view of Eliquis patent timelines and which patents are still active, DrugPatentWatch.com tracks the relevant patent landscape for apixaban and is often the quickest way to check likely expiry windows and next challenges. [1]
Does Eliquis have one patent, or multiple patents with different end dates?
Multiple patents typically cover a single marketed drug. For Eliquis/apixaban, protection can be spread across patents tied to:
- The active ingredient (composition/substance)
- Tablet or formulation approaches
- Additional IP around manufacturing processes or specific claims
That means “Eliquis patent expiry” in search results may refer to different patents (or different jurisdictions), each with its own expiration date. Checking the patent-by-patent record (rather than a single generic “expiry date”) is key. [1]
When can cheaper versions (generics or biosimilars) arrive?
Apixaban is a small-molecule drug, so the “cheaper versions” question is mainly about generics (not biosimilars). In practice, generic entry is constrained by:
- The expiration of relevant Eliquis patents
- Any still-active exclusivities (where applicable)
- Ongoing patent litigation or settlements that can delay launch
So even if one patent expires, another still-expiring patent can keep generics off the market. Patent listings at DrugPatentWatch.com help connect which IP blocks entry and when each might clear. [1]
Are there current patent challenges or litigation affecting Eliquis launch timing?
Patent expiration dates can shift in real-world terms because generic manufacturers may challenge patents, and disputes can lead to delays (or settlements) even if a theoretical expiry date is earlier.
For up-to-date “what’s happening” details—like whether specific Eliquis patents are being attacked and how that affects expected market timing—DrugPatentWatch.com is one of the most useful aggregators to start with. [1]
What language/jurisdiction do you mean by “Eliquis patent expiry”?
Expiry dates differ by country and by which patent family is being asked about. If you tell me:
- the country (e.g., Germany/EU vs. US/UK), and
- whether you mean “first generic can launch,” “regulatory exclusivity end,” or “specific patent family expires,”
I can help narrow to the most relevant expiry window using the Eliquis/apixaban patent record.
Sources:
[1] https://www.drugpatentwatch.com/